最近的HDAC抑制剂对抗乳腺癌的进展
Syed Abdulla Mehmood1, Kantrol Kumar Sahu2, Sounok Sengupta3
1Department of Pharmacology, School of Pharmaceutical Education & Research, Jamia Humdard University, New Delhi, India.
Medical oncology (Northwood, London, England)
|June 9, 2023
概括
基因组脱乙酶抑制剂 (HDACis) 在三阴性乳腺癌 (TNBC) 治疗中表现有前途. 贝利诺斯塔特在分子对接研究中表现出最好的结合亲和力与基因素脱乙酶蛋白.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 三阴性乳腺癌 (TNBC) 缺乏有效的治疗方法,需要新的治疗策略.
- 基因组脱乙酶 (HDACs) 调节细胞过程,对于癌症的发展至关重要.
- 基因组脱乙酶抑制剂 (HDACis) 正在探索它们在TNBC中的治疗潜力.
研究的目的:
- 讨论药理模型和HDACis的结构改变,以有效抑制TNBC.
- 研究HDAC抑制剂对TNBC的治疗潜力.
- 执行HDAC抑制剂的分子对接和动态模拟.
主要方法:
- 对HDACis药法模型和结构修改的分析.
- 对四种HDAC抑制剂进行分子对接研究,对抗胰岛素脱乙酶蛋白.
- 最好的对接化合物的分子动力学模拟.
主要成果:
- 贝利诺斯塔特表现出最高的结合亲和力 (-8.7 kJ/mol) 素脱乙酶蛋白.
- 贝利诺斯塔特与关键氨基酸残留物 (Gly 841,His 669,His 670,Pro 809,His 709) 形成了五种常规的键.
- 对HDAC抑制的结构洞察力为开发新型TNBC治疗提供了基础.
结论:
- HDAC 抑制剂,特别是贝利诺斯塔特,对TNBC治疗具有显著的潜力.
- 药模拟和分子模拟是设计有效的HDACis的宝贵工具.
- 对于TNBC,选择性和多药性HDAC策略的进一步开发是有必要的.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K


